Oral drugs against COVID-19
Background: Five-day oral therapies against early COVID-19 infection have recently been conditionally approved in Europe. In the drug combination nirmatrelvir + ritonavir (nirmatrelvir/r), the active agent, nirmatrelvir, is made bioavailable in clinically adequate amounts by the additional administr...
Gespeichert in:
| Hauptverfasser: | , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
APR 15 2022
|
| In: |
Deutsches Ärzteblatt
Year: 2022, Jahrgang: 119, Heft: 15, Pages: 263-272 |
| ISSN: | 1866-0452 |
| DOI: | 10.3238/arztebl.m2022.0152 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3238/arztebl.m2022.0152 Verlag, lizenzpflichtig, Volltext: https://www.webofscience.com/api/gateway?GWVersion=2&SrcAuth=DOISource&SrcApp=WOS&KeyAID=10.3238%2Farztebl.m2022.0152&DestApp=DOI&SrcAppSID=EUW1ED0DBFBCHlGCUiZBp1AoM9kvE&SrcJTitle=DEUTSCHES+ARZTEBLATT+INTERNATIONAL&DestDOIRegistrantName=Deutscher+Arzte-Verlag+GmbH 
|
| Verfasserangaben: | Gerd Mikus, Kathrin I. Foerster, Theresa Terstegen, Cathrin Vogt, Andre Said, Martin Schulz, Walter E. Haefeli |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1821321359 | ||
| 003 | DE-627 | ||
| 005 | 20230118133011.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 221109s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3238/arztebl.m2022.0152 |2 doi | |
| 035 | |a (DE-627)1821321359 | ||
| 035 | |a (DE-599)KXP1821321359 | ||
| 035 | |a (OCoLC)1361693107 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Mikus, Gerd |e VerfasserIn |0 (DE-588)110903137 |0 (DE-627)691097941 |0 (DE-576)336988710 |4 aut | |
| 245 | 1 | 0 | |a Oral drugs against COVID-19 |c Gerd Mikus, Kathrin I. Foerster, Theresa Terstegen, Cathrin Vogt, Andre Said, Martin Schulz, Walter E. Haefeli |
| 264 | 1 | |c APR 15 2022 | |
| 300 | |b Illustrationen | ||
| 300 | |a 10 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 09.11.2022 | ||
| 520 | |a Background: Five-day oral therapies against early COVID-19 infection have recently been conditionally approved in Europe. In the drug combination nirmatrelvir + ritonavir (nirmatrelvir/r), the active agent, nirmatrelvir, is made bioavailable in clinically adequate amounts by the additional administration of a potent inhibitor of its first-pass metabolism by way of cytochrome P450 [CYP] 3A in the gut and liver. In view of the central role of CYP3A in the clearance of many different kinds of drugs, and the fact that many patients with COVID-19 are taking multiple drugs to treat other conditions, it is important to assess the potential for drug interactions when nirmatrelvir/r is given, and to minimize the risks associated with such interac-tions. Methods: We defined the interaction profile of ritonavir on the basis of information derived from two databases (Medline, GoogleScholar), three standard electronic texts on drug interactions, and manufacturer-supplied drug information. We com-piled a list of drugs and their potentially relevant interactions, developed a risk min -imization algorithm, and applied it to the substances in question. We also compiled a list of commonly prescribed drugs for which there is no risk of interaction with nirmatrelvir/r. Results: Out of 190 drugs and drug combinations, 57 do not need any special measures when given in combination with brief, low-dose ritonavir treatment, while 15 require dose modification or a therapeutic alternative, 8 can be temporarily dis-continued, 9 contraindicate ritonavir use, and 102 should preferably be combined with a different treatment. Conclusion: We have proposed measures that are simple to carry out for the main types of drug that can interact with ritonavir. These measures can be implemented under quarantine conditions before starting a 5-day treatment with nirmatrelvir/r. | ||
| 650 | 4 | |a clearance | |
| 650 | 4 | |a complex | |
| 650 | 4 | |a cyp3a activity | |
| 650 | 4 | |a in-vitro | |
| 650 | 4 | |a induction | |
| 650 | 4 | |a inhibition | |
| 650 | 4 | |a myocardial-infarction | |
| 650 | 4 | |a pharmacokinetic interaction | |
| 650 | 4 | |a ritonavir | |
| 650 | 4 | |a withdrawal | |
| 700 | 1 | |a Foerster, Kathrin |e VerfasserIn |0 (DE-588)118114602X |0 (DE-627)1662507089 |4 aut | |
| 700 | 1 | |a Terstegen, Theresa |e VerfasserIn |0 (DE-588)1242206779 |0 (DE-627)1772156574 |4 aut | |
| 700 | 1 | |a Vogt, Cathrin |e VerfasserIn |0 (DE-588)1272364100 |0 (DE-627)1821323262 |4 aut | |
| 700 | 1 | |a Said, André |e VerfasserIn |0 (DE-588)1060932911 |0 (DE-627)803285485 |0 (DE-576)417056591 |4 aut | |
| 700 | 1 | |a Schulz, Martin |e VerfasserIn |4 aut | |
| 700 | 1 | |a Haefeli, Walter E. |d 1958- |e VerfasserIn |0 (DE-588)124572359 |0 (DE-627)656806141 |0 (DE-576)340514221 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Deutsches Ärzteblatt |b International : a weekly online journal of clinical medicine and public health |d Köln : Dt. Ärzte-Verl., 2006 |g 119(2022), 15, Seite 263-272 |h Online-Ressource |w (DE-627)557878810 |w (DE-600)2406159-1 |w (DE-576)281368007 |x 1866-0452 |7 nnas |a Oral drugs against COVID-19 |
| 773 | 1 | 8 | |g volume:119 |g year:2022 |g number:15 |g pages:263-272 |g extent:10 |a Oral drugs against COVID-19 |
| 856 | 4 | 0 | |u https://doi.org/10.3238/arztebl.m2022.0152 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.webofscience.com/api/gateway?GWVersion=2&SrcAuth=DOISource&SrcApp=WOS&KeyAID=10.3238%2Farztebl.m2022.0152&DestApp=DOI&SrcAppSID=EUW1ED0DBFBCHlGCUiZBp1AoM9kvE&SrcJTitle=DEUTSCHES+ARZTEBLATT+INTERNATIONAL&DestDOIRegistrantName=Deutscher+Arzte-Verlag+GmbH |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20221109 | ||
| 993 | |a Article | ||
| 994 | |a 2022 | ||
| 998 | |g 124572359 |a Haefeli, Walter E. |m 124572359:Haefeli, Walter E. |d 910000 |d 910100 |e 910000PH124572359 |e 910100PH124572359 |k 0/910000/ |k 1/910000/910100/ |p 7 |y j | ||
| 998 | |g 1272364100 |a Vogt, Cathrin |m 1272364100:Vogt, Cathrin |d 910000 |d 910100 |e 910000PV1272364100 |e 910100PV1272364100 |k 0/910000/ |k 1/910000/910100/ |p 4 | ||
| 998 | |g 1242206779 |a Terstegen, Theresa |m 1242206779:Terstegen, Theresa |d 910000 |d 910100 |e 910000PT1242206779 |e 910100PT1242206779 |k 0/910000/ |k 1/910000/910100/ |p 3 | ||
| 998 | |g 118114602X |a Foerster, Kathrin |m 118114602X:Foerster, Kathrin |d 910000 |d 910100 |e 910000PF118114602X |e 910100PF118114602X |k 0/910000/ |k 1/910000/910100/ |p 2 | ||
| 998 | |g 110903137 |a Mikus, Gerd |m 110903137:Mikus, Gerd |d 910000 |d 910100 |d 50000 |e 910000PM110903137 |e 910100PM110903137 |e 50000PM110903137 |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 1 |x j | ||
| 999 | |a KXP-PPN1821321359 |e 4207993878 | ||
| BIB | |a Y | ||
| SER | |a newspaper | ||
| JSO | |a {"type":{"media":"Online-Ressource","bibl":"article-newspaper"},"recId":"1821321359","note":["Gesehen am 09.11.2022"],"relHost":[{"id":{"issn":["1866-0452"],"zdb":["2406159-1"],"eki":["557878810"]},"titleAlt":[{"title":"Deutsches Ärzte-Blatt"}],"note":["Gesehen am 15.8.2025"],"part":{"pages":"263-272","extent":"10","year":"2022","text":"119(2022), 15, Seite 263-272","issue":"15","volume":"119"},"recId":"557878810","type":{"bibl":"newspaper","media":"Online-Ressource"},"pubHistory":["103.2006 -"],"title":[{"title":"Deutsches Ärzteblatt","title_sort":"Deutsches Ärzteblatt"}],"language":["eng","ger"],"disp":"Oral drugs against COVID-19Deutsches Ärzteblatt","physDesc":[{"extent":"Online-Ressource"}],"origin":[{"publisher":"Dt. Ärzte-Verl.","edition":"International : a weekly online journal of clinical medicine and public health","dateIssuedDisp":"2006-","dateIssuedKey":"2006","publisherPlace":"Köln"}]}],"name":{"displayForm":["Gerd Mikus, Kathrin I. Foerster, Theresa Terstegen, Cathrin Vogt, Andre Said, Martin Schulz, Walter E. Haefeli"]},"physDesc":[{"noteIll":"Illustrationen","extent":"10 S."}],"id":{"doi":["10.3238/arztebl.m2022.0152"],"eki":["1821321359"]},"origin":[{"dateIssuedDisp":"APR 15 2022","dateIssuedKey":"2022"}],"language":["eng"],"person":[{"role":"aut","roleDisplay":"VerfasserIn","given":"Gerd","display":"Mikus, Gerd","family":"Mikus"},{"role":"aut","roleDisplay":"VerfasserIn","given":"Kathrin","display":"Foerster, Kathrin","family":"Foerster"},{"family":"Terstegen","given":"Theresa","role":"aut","roleDisplay":"VerfasserIn","display":"Terstegen, Theresa"},{"family":"Vogt","role":"aut","roleDisplay":"VerfasserIn","given":"Cathrin","display":"Vogt, Cathrin"},{"family":"Said","display":"Said, André","role":"aut","roleDisplay":"VerfasserIn","given":"André"},{"family":"Schulz","roleDisplay":"VerfasserIn","role":"aut","given":"Martin","display":"Schulz, Martin"},{"display":"Haefeli, Walter E.","roleDisplay":"VerfasserIn","role":"aut","given":"Walter E.","family":"Haefeli"}],"title":[{"title":"Oral drugs against COVID-19","title_sort":"Oral drugs against COVID-19"}]} | ||
| SRT | |a MIKUSGERDFORALDRUGSA1520 | ||